Organisation paid for research Program year 2025 Source: CMS Open Payments

Center for Assisted Reproduction

Neither a doctor nor a teaching hospital

Research payments

$2,611,309

117 payments

Through program year 2025, Center for Assisted Reproduction is reported as receiving $2,611,309 in research payments, across 117 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $266,505 7
2024 Research $82,495 11
2023 Research $101,086 6
2022 Research $2,018 5
2021 Research $175,526 29
2020 Research $350,881 33
2019 Research $1,632,797 26

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ferring International Pharmascience Center US $2,165,894 91 payments
  2. IBSA Institut Biochimique SA $424,635 23 payments
  3. Gilead Sciences, Inc. $20,779 2 payments
  4. Merck Sharp & Dohme Corporation $0 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 18-34 Years Undergoing Assisted Reproductive Technology $864,333 30 payments
  2. A Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Trial Investigating the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Women Aged 35-42 Years Undergoing Assisted Reproductive Technology $821,820 29 payments
  3. PROGRESS - Subcutaneous PROgesterone in fRozen-thawed single Euploid blaStocyst tranSfer $424,635 23 payments
  4. A Randomized, Double-blind Double-dummy Trial Comparing MENOPUR Solution for Injection in a Pre-filled Pen and MENOPUR Powder and Solvent for Solution for Injection (Menotropins for Injection) in a GnRH Agonist Cycle in Women Aged 18-42 Years Undergoing an Assisted Reproductive Technology Program $254,500 24 payments
  5. A Prospective, Multi-Center, Non-Comparative Trial of the Clinical Safety of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology ART Procedures $225,242 8 payments
  6. A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease $18,882 1 payment
  7. A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease $1,897 1 payment
  8. A Phase 3, single arm, clinical trial to study the contraceptive efficacy and safety of the MK-8342B etonogestrel 17 -estradiol vaginal ring in healthy women 18 years of age and older, at risk for pregnancy $0 1 payment
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $168,149 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record